Results 21 to 30 of about 265 (112)
Advancing antihypertensive drug development
Hypertension affects more than a billion individuals worldwide and remains a major cause of cardiovascular morbidity and mortality. Despite advances in therapies, optimal blood pressure control remains elusive for many patients because of treatment ...
Wang, Xin
core +11 more sources
Molecular Therapies in Cardiovascular Diseases: Small Interfering RNA in Atherosclerosis, Heart Failure, and Hypertension. [PDF]
Int J Mol Sci, 2023 Small interfering RNA (siRNA) represents a novel, fascinating therapeutic strategy that allows for selective reduction in the production of a specific protein through RNA interference.
Sarzani R +5 more
europepmc +2 more sources
Exploratory Studies on RNAi-Based Therapies Targeting Angiotensinogen in Hypertension: Scoping Review. [PDF]
J Pers MedBackground: Systemic arterial hypertension contributes to cardiovascular morbidity and mortality worldwide. Many patients cannot achieve optimal blood pressure (BP) control with traditional therapies, which often results in poor patient adherence and ...
Menezes Junior ADS +4 more
europepmc +2 more sources
Enhanced liver-targeted delivery with ribofuranose-based GalNAc conjugates. [PDF]
Mol Ther Nucleic AcidsThis study highlights that small geometric constraints with the GalNAc moiety can tune receptor engagement and serum stability. The ribofuranose ring is a 2\u2032-O-methyl modification, used in the siRNA backbone to improve metabolic stability and reduce
Pradeep SP, Ruchi R, Bahal R.
europepmc +2 more sources
Small interfering RNA: Discovery, pharmacology and clinical development—An introductory review
British Journal of Pharmacology, Volume 180, Issue 21, Page 2697-2720, November 2023., 2023 Abstract Post‐transcriptional gene silencing targets and degrades mRNA transcripts, silencing the expression of specific genes. RNA interference technology, using synthetic structurally well‐defined short double‐stranded RNA (small interfering RNA [siRNA]), has advanced rapidly in recent years.
Priyanga Ranasinghe +3 more
wiley +1 more source
Emerging insights and future prospects for therapeutic application of siRNA targeting angiotensinogen in hypertension [PDF]
, 2023 IntroductionHypertension is the main global risk factor for cardiovascular disease. Despite this, less than half of treated hypertensive patients are controlled.
Addison, Melisande L +2 more
core +1 more source
The contribution of extracellular RNA and its derived biomaterials in disease management
BMEMat, Volume 3, Issue 2, June 2025.The implications of exRNA's biological function and the structural uniqueness of RNA help establish a close connection between RNA, material, and modern medicine. Abstract The RNA found in the circular system is known as extracellular RNA (exRNA). This kind of RNA has been found to play a biological role similar to that of a messenger. They can be used
Yu Wei +8 more
wiley +1 more source
The Journal of Physiology, Volume 603, Issue 9, Page 2487-2516, 1 May 2025.Abstract figure legend The carotid body develops aberrant high activity in chronic heart failure, resistant hypertension, obstructive sleep apnoea (OSA) and diabetes. Hyperactivity of the carotid body leads to both high tonicity and increased sensitivity of the arterial chemoreflex with resultant sympathoexcitation.
Tymoteusz Żera +7 more
wiley +1 more source
Zilebesiran: o futuro do controle da hipertensão [PDF]
Introduction: the relationship between the kidney and blood pressure has been studied and investigated over time. This is due to the fact that the kidney has had a primordial influence in the development and the long –term regulation of blood pressure ...
Cobo Álvarez, Daniela Abigaíl +2 more
core +1 more source